GlassScriptPhysician profile
Erin Olivia Wade
NPI 1811769029
$5,052.25
in general payments reported to CMS, 2019-2025
27 companies · $2,302 in 2025
The $2,302 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $92.99 · 2024: $2,657 · 2025: $2,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,680 · Education: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,680.28 |
| Education | $371.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $879.89 | 2024-2025 | Tremfya |
| Abbvie INC. | $633.63 | 2023-2025 | |
| Galderma Laboratories, L.P. | $374.75 | 2024-2025 | Aklief, Nemluvio, Oracea |
| Leo Pharma INC. | $356.85 | 2024-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $302.36 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $294.42 | 2023-2025 | |
| Incyte Corporation | $268.00 | 2024-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $265.86 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $254.71 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $226.65 | 2024-2025 | Sotyktu |
| Ucb, INC. | $204.25 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $199.73 | 2024-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $105.90 | 2024-2025 | Taltz, Ebglyss, Zepbound |
| Pfizer INC. | $93.33 | 2024-2025 | |
| Botanix Sb INC | $92.33 | 2025 | Sofdra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $90.64 | 2024-2025 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $72.68 | 2024-2025 | Cabtreo, Jublia, Arazlo |
| Biofrontera INC. | $64.44 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Solta Medical, A Division of Bausch Health US, LLC | $45.04 | 2025 | Clear & Brilliant, Fraxel |
| Amgen INC. | $43.09 | 2025 | Otezla |
| Mimedx Group, INC. | $42.93 | 2024 | |
| Revance Therapeutics, INC. | $32.60 | 2025 | Daxxify |
| Cipher Pharmaceuticals US LLC | $25.22 | 2025 | Spinosad, Natroba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.65 | 2024 | Spevigo |
| Verrica Pharmaceuticals INC. | $24.43 | 2024 | Ycanth |
| Vertical Pharmaceuticals, LLC | $18.28 | 2024 | Dsuvia |
| Kerecis Limited | $15.59 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.